The race to bring an oral obesity agent to market is heating up. Novo Nordisk A/S presented detailed results for the oral version of its GLP-1 agonist semaglutide on 25 June at the American Diabetes Association (ADA) annual meeting from the Phase IIIa OASIS 1 clinical trial, with 15.1% mean weight loss observed in overweight and obese adults versus 2.4% for placebo (p<0.0001), confirming topline results release in May. The readout took place two days after the presentation of Phase II data at ADA for Eli Lilly and Company’s oral GLP-1 drug orforglipron, which could be a formidable competitor.
With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA
Lilly’s Oral GLP-1 Also Impressed
Novo’s oral semaglutide generated 15.1% weight loss at 68 weeks in the Phase IIIa OASIS 1 study, but Lilly’s orforglipron provided up to 14.7% weight loss at 36 weeks in Phase II without reaching a plateau.
More from Clinical Trials
More from R&D
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.